Rigel completes patient enrollment in first phase 3 study of fostamatinib in ITP
The results from the initial trial are anticipated in the middle of this year, with the results from the second study expected soon thereafter. The FIT program features
ProBio has entered into an exclusive worldwide licensing agreement with South Korean biotechnology firm AbTis to develop and commercialise an early-stage therapeutic antibody asset.
Preclinical studies of RAD1901 have shown consistent and robust single agent anti-tumor activity in multiple wild type and ESR1-mutant breast cancer models and tumor regression when combined with